Clinical trial NCT05589597: EO4010 in Previously Treated Metastatic Colorectal Carcinoma
Official title: A Global Multicenter Phase 1/2 Trial of EO4010, a Novel Microbial Derived Peptide Therapeutic Vaccine, in Combination With Nivolumab and/or Bevacizumab, for Treatment of Patients With Previously Treated Metastatic Colorectal Carcinoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Colorectal Cancer Metastatic
Lead sponsor: Enterome
Sponsor class: INDUSTRY
First posted: 2022-10-21
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Multi-cohort
Primary purpose: TREATMENT

Brief summary: Open-label multicenter study

Detailed description: This is an open-label, multicenter, FIH, phase 1/2 trial to assess safety, tolerability, immunogenicity, and preliminary efficacy of the microbial-derived therapeutic vaccine EO4010 in combination with nivolumab and/or bevacizumab for treatment of patients with unresectable, previously treated, metastatic colorectal cancer

Eligibility criteria: Inclusion Criteria:

1. Provided written informed consent
2. Histological confirmation of advanced non-resectable colorectal adenocarcinoma
3. Patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for
4. Progression during or within 3 months following the latest administration of standard therapies
5. Age ≥ 18 years old
6. Human leukocyte antigen (HLA)-A2 positive
7. ECOG performance status 0 or 1
8. Measurable disease according to Response Evaluation Criteria in Solid Tumors criteria (RECIST)
9. Patients with a life expectancy of at least 3 months
10. Female patients of childbearing potential must have a negative serum pregnancy test
11. Patients following recommendations for contraception
12. Patients willing and able to comply with the study procedures

Exclusion Criteria:

1. Patients treated with dexamethasone \> 2 mg/day or equivalent within 14 days before randomization, unless required to treat an adverse event
2. Patients treated with radiotherapy within 12 weeks, and cytotoxic chemotherapy therapy within 28 days
3. Patients with persistent Grade ≥ 2 toxicities (according to NCI-CTCAE v5.0). Toxicities must be resolved for at least 2 weeks to Grade 1 or less
4. Patients who have received any prior treatment with compounds targeting PD1, PDL1, CTLA-4, or similar compounds
5. Patients who have previously received trifluridine/tipiracil (TAS-102) or regorafenib
6. Patients with prior exposure to EO2401, EO2040, or EO4010, i.e. therapeutic vaccine compounds including all or some components of EO4010
7. Patients with the following abnormal laboratory values:

   1. Lymphocyte count decreased, grade 2 (lymphocytes \<800 - 500/mm3; \<0.8 - 0.5 x 109/L), or worse grade
   2. Hemoglobin \< 10 g/dL (6.2 mmol/L); transfusion is acceptable to reach the value
   3. Absolute neutrophil count decrease (\<1.5 x109/L)
   4. Platelet count decrease (\< 75 ×109/L)
   5. Total bilirubin \> 1.5 ×upper limit of normal
   6. Alanine aminotransferase (ALT) \> 3 ×ULN; if disease metastatic to the liver \> 5 xULN
   7. Aspartate aminotransferase (AST) \> 3 ×ULN; if disease metastatic to the liver \> 5 xULN
   8. Serum creatinine increase (\> 1.5 ×ULN)
   9. Abnormal thyroid function per local laboratory levels
8. Other malignancy or prior malignancy with a disease-free interval of less than 3 years prior to ICF signing; except those treated with surgical intervention and an expected low likelihood of recurrence
9. Patients with clinically significant active infection, cardiac disease, significant medical or psychiatric disease/condition
10. Patients with suspected autoimmune or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g., Guillain-Barré syndrome)
11. Patients with a history of solid organ transplantation or allogeneic hematopoietic stem cell transplantation
12. Patients with a history or known presence of tuberculosis
13. Pregnant and breastfeeding patients
14. Patients with a history or presence of human immunodeficiency virus (HIV) and/or active hepatitis B virus (HBV)/hepatitis C virus (HCV)
15. Uncontrolled central nervous system (CNS) metastasis
16. Patients who have received live or attenuated vaccine therapy used for prevention of infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the first dose of study drug
17. Patients with a history of hypersensitivity to any excipient, or active substance, present in the pharmaceutical forms of applicable study treatments
18. Patients under treatment with immunostimulatory or immunosuppressive medications
19. Patients who have received treatment with any other investigational agent, or participation in another clinical trial

Primary outcomes:
measure: Safety and tolerability of EO4010 in combination with nivolumab and/or bevacizumab
timeFrame: 12months
Secondary outcomes:
measure: Percentage of patients with shown immunogenicity
timeFrame: 12 months
measure: Overall response rate
timeFrame: 12 months
measure: Disease control rate
timeFrame: 12 months
measure: Time to response
timeFrame: 12 months
measure: Duration of response
timeFrame: 12 months
measure: Progression free survival
timeFrame: 4months
measure: Overall survival to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up
timeFrame: 12 months
Other outcomes:
Locations:
city: Houston
country: United States
facility: MD Anderson
state: Texas
city: Besançon
country: France
facility: Hôpital Jean Minjoz
city: Montpellier
country: France
facility: ICM Val d'Aurelle
city: Paris
country: France
facility: Saint Antoine hospital
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d'Hebron
city: Valencia
country: Spain
facility: Llavero-Hospital Clínico Universitario
Study officials:
affiliation: Enterome
name: Jan Fagerberg
role: STUDY_DIRECTOR
References: